• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Radiopharm Theranostics Limited

    5/12/25 6:03:40 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RADX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Radiopharm Theranostics Limited

    (Name of Issuer)


    Ordinary Shares, no par value and American Depositary Shares, each representing three hundred Ordinary Shares, no par value

    (Title of Class of Securities)


    75041J101

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    75041J101


    1Names of Reporting Persons

    Regal Funds Management Pty Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    AUSTRALIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    210,721,080.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    210,721,080.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    210,721,080.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.03 %
    12Type of Reporting Person (See Instructions)

    FI

    Comment for Type of Reporting Person:  The number of shares beneficially owned includes: (i) 183,448,380 Ordinary Shares, no par value ("Ordinary Shares") and (ii) 90,909 American Depositary Shares, each representing three hundred Ordinary Shares.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Radiopharm Theranostics Limited
    (b)Address of issuer's principal executive offices:

    Level 3, 62 Lygon Street, Carlton Vic, AUSTRALIA, 3053
    Item 2. 
    (a)Name of person filing:

    Regal Funds Management Pty Limited and Regal Partners Limited
    (b)Address or principal business office or, if none, residence:

    Level 46, Gateway, 1 Macquarie Place, Sydney NSW 2000
    (c)Citizenship:

    Australian
    (d)Title of class of securities:

    Ordinary Shares, no par value and American Depositary Shares, each representing three hundred Ordinary Shares, no par value
    (e)CUSIP No.:

    75041J101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    FI
    Item 4.Ownership
    (a)Amount beneficially owned:

    210,721,080
    (b)Percent of class:

    9.03%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    210,721,080

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    210,721,080

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Regal Funds Management Pty Limited
     
    Signature:/s/ Kenny Ho
    Name/Title:Company Secretary
    Date:05/12/2025
    Get the next $RADX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RADX

    DatePrice TargetRatingAnalyst
    3/12/2025$15.00Buy
    B. Riley Securities
    More analyst ratings

    $RADX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer

    RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinity Tb-161 antitumor activity driven by the dual emission of beta particles and Auger electrons SYDNEY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has been granted Bellberry Human Research Ethics Committee (HREC) approval in Australia to initiate its First-In-Human (FIH) Phase 1 clinical trial of its Kallikrein Related Peptidase 3 (KLK3)-targeting radiotherapeutic, RAD 402, for t

    11/18/25 8:30:00 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases

    Early patient data from Phase 2b clinical trial showed significant and selective tumor uptake in brain metastases compared to MRI Phase 2b clinical trial expected to complete enrollment and have topline data in 1H26 SYDNEY, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the Phase 2b trial evaluating RAD101 imaging in brain metastases has achieved 50% patient enrollment threshold. "Enrolling 50% of the patients in our Phase 2b study of RAD101 is a meaningful achievement for

    11/17/25 8:00:00 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204

    Data Safety Monitoring Committee approves advancing to a higher dose of 90mCi The first two Cohorts' patients show tumor uptake and a favourable safety profile SYDNEY, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the completion of enrollment for the second cohort of patients in the Phase 1 dose escalation trial of 177Lu-RAD204 in PD-L1 positive advanced cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), triple-negative breast ca

    11/12/25 8:30:00 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RADX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Radiance Medical with a new price target

    B. Riley Securities initiated coverage of Radiance Medical with a rating of Buy and set a new price target of $15.00

    3/12/25 7:30:55 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RADX
    SEC Filings

    View All

    Amendment: SEC Form 20-F/A filed by Radiopharm Theranostics Limited

    20-F/A - Radiopharm Theranostics Ltd (0001949257) (Filer)

    12/10/25 6:18:17 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Radiopharm Theranostics Limited

    6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

    12/3/25 9:27:18 PM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Radiopharm Theranostics Limited

    6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

    11/25/25 6:48:22 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RADX
    Leadership Updates

    Live Leadership Updates

    View All

    Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

    SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company's Scientific Advisory Board (SAB). Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He w

    7/22/25 8:00:00 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care